PERIOMED ORIGINAL 074 NOVEMBER 2026

ORAL CANCER · SYSTEMIC VULNERABILITY · SURVEILLANCE

Systemic conditions and oral squamous cell carcinoma.

Genetic susceptibility, immunosuppression and diabetes.

DNA REPAIR
Inherited susceptibilityIMMUNE SURVEILLANCE
Transplantation and HIVMETABOLIC CONTEXT
Diabetes mellitusOSCC
RISK CONTEXT

GENETICSusceptibility can be profound.

IMMUNESome groups need defined lifelong surveillance.

METABOLICAssociation does not establish causation.

FIRST AUTHOR · MEDICAL SCIENCESSofia Cominoli, MDItaly

SECOND AUTHOR · PREVENTION, PUBLIC HEALTH & EDUCATIONMukund Gupta, MD, MBBS, D.CMH.India

SCIENTIFIC REVIEW · MEDICAL SCIENCESLas Latif Hussain, MDIraq

THE CLINICAL QUESTION

The same cancer diagnosis can emerge from very different risk contexts.

Tobacco and alcohol remain central preventable risks for oral squamous cell carcinoma. Yet selected systemic conditions can materially change when disease appears, how strongly risk is elevated and how closely a patient should be followed.

The evidence is unequal. A DNA-repair disorder, allogeneic transplantation and diabetes should not be placed on one flat list. This Original separates inherited susceptibility, altered immune surveillance and metabolic association so clinical action remains proportionate to the evidence.

INHERITED SUSCEPTIBILITY

When genome maintenance changes the starting level of risk.

Rare disorders can produce early and substantial susceptibility even without the usual pattern of tobacco and alcohol exposure.

FANCONI ANEMIA500–700×

Reported HNSCC risk relative to the general population

Registry data place the median age at diagnosis near 31 years. Oral cavity tumours, particularly of the tongue and buccal mucosa, are prominent. [4] [5]

Interpretation boundary: many oral reports are case based, and transplantation is a common co-exposure.

XERODERMA PIGMENTOSUM

Defective nucleotide-excision repair

Oral and lip cancers have been reported, although ultraviolet exposure remains a central environmental driver and oral-specific evidence is limited. [1] [7]

DYSKERATOSIS CONGENITA

Critically short telomeres and cancer susceptibility

Cohort data indicate a marked burden of head and neck and tongue cancers. Annual dental and otolaryngological assessment has been recommended. [8] [10]

THE CLEAREST ACQUIRED HIGH-RISK SETTING

Allogeneic HCT changes both risk and surveillance.

Secondary oral cancer risk increases with time after transplantation and is greatest among patients who develop chronic graft-versus-host disease. Autologous transplantation appears to carry only a slight elevation. [10]

7–16×REPORTED SECONDARY ORAL CANCER RISK

6–12MONTHS BETWEEN LIFELONG ORAL EXAMINATIONS

01ALLOGENEIC HCT

→

02cGVHD AND LONG-TERM EXPOSURE

→

03PERSISTENT OR CHANGING MUCOSA

→

04BIOPSY OR SPECIALIST ASSESSMENT

A suspicious abnormality should not be attributed automatically to oral cGVHD. Treating active mucosal disease may aid interpretation, but persistent or suspicious lesions still require investigation.

OTHER IMMUNOCOMPROMISED POPULATIONS

A signal exists.
A single schedule does not.

SOLID ORGAN TRANSPLANTATION

Higher incidence with broad outcome definitions

A Swedish cohort observed 17 oral cancers compared with 2.69 expected cases. The category included major salivary-gland malignancies and was not restricted to OSCC; lip cancer was analysed separately. [9]

HIV INFECTION

Modest elevations with residual uncertainty

Registry analyses report higher oral tongue and oral cavity SCC incidence. Smoking, alcohol and population characteristics may contribute, arguing against one large uniform effect of immunosuppression. [11]

Regular oral examination is clinically reasonable in these groups. This is different from the formal lifelong schedule established for allogeneic HCT survivors.

METABOLIC CONTEXT

Biological plausibility and epidemiological association are not causal proof.

Hyperglycaemia may promote oxidative stress, inflammatory signalling and metabolic changes. Human evidence, however, remains observational and vulnerable to confounding by age, tobacco, alcohol, obesity, comorbidity and access to care.

1.41OR FOR ORAL CANCER IN THE ORAL-CAVITY SUBGROUPVery-low-certainty evidence with substantial heterogeneity. [3]

1.69HR FOR OVERALL SURVIVALTen cohorts combining oral and oropharyngeal cancer. [12]

Good metabolic control remains important for established health benefits. It has not been shown to prevent OSCC.

EVIDENCE AT A GLANCE

Different contexts require different clinical responses.

01VERY HIGH SUSCEPTIBILITY

Fanconi anemia

Regular oral surveillance from childhood and specialist coordination.

Much oral-outcome evidence is case based; transplantation is a frequent co-exposure.

02MARKED EXCESS RISK

Dyskeratosis congenita

Annual dental and otolaryngological assessment; closer follow-up after HCT.

Rare disorder with limited oral-specific prospective evidence.

037–16× SECONDARY ORAL CANCER RISK

Allogeneic HCT

Lifelong oral surveillance at least every 6–12 months.

Risk varies with time, underlying disease, cGVHD and treatment history.

04HIGHER ORAL AND LIP CANCER INCIDENCE

Solid organ transplantation

Regular oral examination is advisable.

Outcome definitions are broad and no universal interval is established.

05MODESTLY ELEVATED INCIDENCE

HIV infection

Include oral examination in comprehensive long-term care.

Shared exposures and population differences may contribute.

06EPIDEMIOLOGICAL ASSOCIATION

Diabetes mellitus

Assess lesions promptly and manage diabetes for established health benefits.

Observational evidence does not establish independent causation.

WHAT CHANGES AT THE CHAIRSIDE

Systemic history becomes part of oral cancer assessment.

Ask beyond dental history

Record inherited disorders, transplantation, cGVHD, immunosuppressive therapy, HIV and diabetes alongside established exposures.

Examine systematically

Inspect and palpate the oral mucosa rather than limiting the visit to the patient’s presenting complaint.

Interpret the context

Combine lesion features with age, systemic diagnosis, treatment history, tobacco and alcohol exposure.

Escalate without delay

Persistent, unexplained or changing lesions require biopsy or specialist assessment when indicated.

Follow proportionately

Use condition-specific guidance for defined high-risk groups instead of applying one interval to every patient.

Systemic context never replaces assessment of lesion site, appearance, evolution, tobacco and alcohol exposure or histopathology.

THE INTERPRETATION BOUNDARY

What this evidence does not justify.

One surveillance interval for every medically complex patient.

A claim that diabetes independently causes OSCC.

Dismissal of a suspicious lesion because inflammation or cGVHD is already present.

A promise that improving metabolic control prevents oral cancer.

WHAT RESEARCH MUST SOLVE

Define risk precisely enough to guide care without flattening distinct conditions.

Separate anatomical outcomes

Distinguish oral cavity SCC from oropharyngeal, lip and salivary-gland malignancies.

Build rare-disease cohorts

Move beyond case reports through registries and multicentre collaboration.

Measure treatment exposure

Track cGVHD, immunosuppression and time since transplantation prospectively.

Resolve the diabetes question

Separate occurrence from prognosis and account for glycaemic control and major confounders.

THE BOTTOM LINE

Systemic vulnerability matters.
Its meaning is condition specific.

Inherited defects affecting genome maintenance and allogeneic transplantation define high-risk settings that justify sustained surveillance. Solid organ transplantation and HIV show less uniform signals. Diabetes remains an epidemiological association rather than an established independent cause.

Integrate systemic history. Investigate suspicious lesions. Keep every claim proportional to the evidence.

REFERENCES